FORT LAUDERDALE, Fla., Sept. 17, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the upcoming presentation of an abstract regarding the Sylvester Comprehensive Cancer Center at the University of Miami proof-of-concept studies titled, Risk Stratification System for Oral Screening, at the Boston University / Dana-Farber Head & Neck Cancer Symposium, taking place in Boston, MA on September 21, 2015 at the Boston University School of Management. These studies provided direction for the clinical development of Vigilant Biosciences OncAlert Rapid Point-of-Care Test and OncAlert CD44 + Total Protein Lab Test.
Details for the poster presentation are as follows:
Monday, September 21, 2015 8:00 AM – 5:00 PM, Metcalf Trustee Ballroom, 1 Silber Way, Boston, MA
- Poster 17, "Risk Stratification System for Oral Screening," Researchers: Lutecia H. Mateus Pereira, Isildinha M. Reis, Erika P. Reategui, Claudia Gordon, Sandra Saint-Victor, Robert Duncan, Carmen Gomez, Stephanie Bayers, Penelope Fisher, Aymee Perez, W. Jarrard Goodwin, Jennifer J. Hu, Elizabeth J. Franzmann
The schedule of events can be viewed online through the symposium website at http://www.bu.edu/dental/research/head-neck-cancer-symposium/.
About the OncAlert System
Vigilant's initial products comprising the OncAlert System includes the OncAlert Rapid Point-of-Care Test and the OncAlert CD44 + Total Protein Lab Test. Both products in the OncAlert System are based on patented technology that detects specific protein markers associated with an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The test can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume alcohol, and people with human papillomavirus (HPV)). Both the rapid point-of-care test and the lab assay that comprise the OncAlert System are currently under the CE Mark registration approval process. The OncAlert System is not currently available for sale in the United States.
About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. The Vigilant Biosciences™ OncAlert™ System point-of-care and lab assay products are currently undergoing the CE Mark registration approval process and not yet available for sale in any market at this time. For more information, visit www.vigilantbiosciences.com.
SOURCE Vigilant Biosciences, Inc.